JMP Securities Initiates Coverage On Quince Therapeutics with Market Outperform Rating, Announces Price Target of $9
Author: Benzinga Newsdesk | August 05, 2025 08:40am
JMP Securities analyst Jonathan Wolleben initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform rating and announces Price Target of $9.